INTERNATIONAL PATENT: SANA BIOTECHNOLOGY, INC. FILES APPLICATION FOR "HYPOIMMUNOGENIC CD22-TARGETED CAR T CELLS FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY B CELL LYMPHOMAS"

GENEVA, May 15 -- SANA BIOTECHNOLOGY, INC. (88 East Blaine Street, Suite 400Seattle, Washington 98102) filed a patent application (PCT/US2024/053852) for "HYPOIMMUNOGENIC CD22-TARGETED CAR T CELLS FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY B CELL LYMPHOMAS" on Oct 31, 2024. With publication no. WO/2025/096757, the details related to the patent application was published on May 08, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): KOUROS-MEHR, Hosein (c/o Sana Biotechnology, Inc.188 East Blaine Street, Suite 400Seattle, Washington 98102)

Abstract: The present disclosure provides methods ...